Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates
about
Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavirCrystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: Mechanism of drug recognition and resistanceVirologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South AfricaTemporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected AdultsTherapeutic implications of hepatitis C virus resistance to antiviral drugs.Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsLow lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited settingAssociation of first-line and second-line antiretroviral therapy adherence.Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria.Highly resistant HIV-1 proteases and strategies for their inhibition.Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavirLopinavir/ritonavir in the treatment of human immunodeficiency virus infection.Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavirLopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.Second generation HIV protease inhibitors against resistant virus.2014 Update of the drug resistance mutations in HIV-1Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.HIV-2 Protease resistance defined in yeast cells.Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.
P2860
Q27650863-3E4C359F-0FC3-4FA7-AE39-FEE227AA55E5Q27678735-005EC47A-3365-4041-A385-BF91DC7C0D60Q28481468-D8DE36FE-5181-47B4-92A5-D53250AED4ADQ33750994-5A94A052-28B5-4ACC-A7B8-98FCDEA7326DQ34409020-C72930EF-4223-421E-BA9B-0E26893621B9Q34730950-18C4B989-A838-4736-8218-BBFE036E58A8Q34778123-FB7C2919-C63F-4E2E-9F47-7D10A7BADEEDQ34801978-EE8FFCE8-B331-403C-8163-238BD71ECDEEQ34998736-9D466ED1-A48C-4091-9AC1-BAED37AA7E97Q35907004-20C1BD83-8921-4436-B42A-2E2588DF9021Q36094935-36BFAA66-7898-4D13-910A-B495F92AAEECQ36094944-7B0DBC4F-E6CA-45D1-A488-63625EB29BE7Q36222013-3C37171D-B53F-4213-996F-DF8D02E40718Q36424925-5EC4EA4E-FA4C-4380-9185-FD00EA340FC3Q36723780-7DAD9A2D-7F23-43EC-84BA-BAA3FE5E534AQ36727919-AFA6CD27-AB96-411D-B4B0-181C974410EFQ37256366-821E3F32-15AD-4493-AA2E-445EFD49FA8BQ38089895-DA5DFB3D-D996-4358-A0A0-0E50404E671EQ39498339-64B49D30-2A1F-41B9-A548-653477BA5584Q43057951-DAF8F9C7-077B-433C-BF4D-7C2238F0375CQ43249256-7D9C6F59-72EF-41E9-8594-9E92667D19A4Q49711913-CBE04921-2641-4B09-A8E8-2AE301CA074F
P2860
Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Selection of resistance in pro ...... tterns and baseline correlates
@en
type
label
Selection of resistance in pro ...... tterns and baseline correlates
@en
prefLabel
Selection of resistance in pro ...... tterns and baseline correlates
@en
P2093
P2860
P1433
P1476
Selection of resistance in pro ...... tterns and baseline correlates
@en
P2093
Akhteruzzaman Molla
Dale J Kempf
Hongmei Mo
Kathryn King
Martin S King
Scott Brun
P2860
P304
P356
10.1128/JVI.79.6.3329-3338.2005
P407
P577
2005-03-01T00:00:00Z